Egalet Corporation is a specialty pharmaceutical company developing and focuses on commercializing, abuse-deterrent oral products for the treatment of pain and in other indications. Using its technology platform, it has developed a pipeline of clinical-stage, opioid-based product candidates in tablet form that are designed to deter abuse by physical and chemical manipulation while also providing the ability to tailor the release of the active pharmaceutical ingredient (API). The Company’s lead product candidate, Egalet-001, is an abuse-deterrent, extended-release, oral morphine formulation in development for the treatment of moderate to severe pain. Its second product candidate, Egalet-002, is an abuse-deterrent, extended-release, oral oxycodone formulation in development for the treatment of moderate to severe pain.
Address
Suite 1050, 460 East Swedesford Road
WAYNE, PA 19087
United States
Website
http://www.egalet.com
Key stats and ratios
|
| Net profit margin | - | -449.46% |
| Operating margin | - | -440.97% |
| EBITD margin | - | -407.33% |
| Return on average assets | -220.69% | -140.37% |
| Return on average equity | - | - |
| Employees | 18 |
